Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AME Study of Denifanstat in Healthy Male Subjects
NCT05657834Phase 1Completed
- Sponsor
- Sagimet Biosciences
- Start
- Nov 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of denifanstat in metabolic dysfunction-associated steatohepatitis (MASH), sponsored by Sagimet Biosciences. Primary endpoints: Area Under the Curve to Infinity up to 22 days, Amount of [14C]TVB-2640 Excreted in Urine up to 22 days and 1 more. Started Nov 2022; status: completed.
02
Drugs
denifanstat
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NCT05657834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05657834.